Clinical trials: Oral Anticoagulant
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Venous Thromboembolic Disease
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.
- Trial name
- BAT-VTE (NCT05627375)
- Testing
- Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP)
- Where
- 28 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Deep Vein Thrombosis, Pulmonary Embolism
Impact of Pharmacists' Training on Oral Anticoagulant Counseling
This study evaluates the impact of community pharmacists' educational training on the nature and adequacy of counseling provided to patients on warfarin, an oral anticoagulant.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT03999905
- Testing
- Counseling training
- Where
- Nigeria
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Ibadan
Oral Anticoagulants, Invasive Procedure
Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology
Patients receiving long-term oral anticoagulant (defined as duration of treatment of at least 1 month of Direct Oral Anticoagulant (DAOC) or Vitamin K Antagonist (VKA)) and referred for an invasive procedure (oral surgery…
- Trial name
- PRADICO (NCT03150303)
- Where
- France
- Volunteers
- 532 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Emergency Care for Severe Bleeding While on Anticoagulants
Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants
The study is assessing the impact of an expert eCRF on the management of severe bleeding in the administration of Prothrombin Complex Concentrate in patients treated with oral anticoagulants and adherence to recommendations or…
- Trial name
- NCT03320603
- Testing
- Expert eCRF, Prothrombin Complex Concentrate
- Where
- 26 sites in France
- Volunteers
- 397 people
- Sponsor
- Octapharma
Anticoagulants; Circulating, Hemorrhagic Disorder
Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
This is a prospective, multicentric, randomized, open labeled superiority trial This study aims to evaluate the efficacy of oral activated charcoal for improving elimination of direct oral anticoagulants ( Rivaroxaban, Apixaban)…
- Trial name
- CACAOD (NCT02969746)
- Testing
- Activated Charcoal
- Where
- 6 sites in France
- Sponsor
- University Hospital, Angers
Atrial Fibrillation
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).
- Trial name
- NCT02792335
- Testing
- apixaban, dabigatran, rivaroxaban
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Surgery, Oral, Hemorrhage
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs. To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in…
- Conditions
- Surgery, Oral, Hemorrhage, Postoperative Complications, Oral Surgical Procedures
- Trial name
- NCT04662515
- Testing
- Type of surgery, Dabigatran, Rivaroxaban
- Where
- 2 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Malmö University
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
DOAC ADRs Retrospective Study on Genetic Variations
The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e.
- Trial name
- DARES1 (NCT04580589)
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cipherome, Inc.
Oral Anticoagulant, Adherence
Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation
The rhythm disorders of Atrial Fibrillation (AF) require continuous treatment with anticoagulants to prevent stroke. The introduction of direct oral anticoagulants (DOACs) quickly supplanted the administration of anti-vitamin K…
- Trial name
- 3AOD (NCT05469308)
- Testing
- questionary
- Where
- France
- Volunteers
- 883 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Atrial Fibrillation, Stroke
Canadian Community Utilization of Stroke Prevention Study - Emergency Department
Atrial fibrillation (AF) is a common heart condition, and increases the risk of stroke by six times. There are several medications (blood thinners) that can prevent strokes in AF patients.
- Trial name
- C-CUSP ED (NCT02358655)
- Testing
- Retrospective review of OAC prescription, Prescription of OAC in ED, Community AF clinic
- Where
- 5 sites in Canada
- Volunteers
- 360 people
- Sponsor
- Population Health Research Institute
Anticoagulant-induced Bleeding, Dental Diseases
Intra- and Post- Operative Bleeding After Simple Dental Extraction in Direct Oral Anticoagulant Therapy
Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral…
- Trial name
- NOADB (NCT03124030)
- Testing
- simple dental extraction
- Where
- Italy
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Trieste
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Postpolypectomy Bleeding
Timing of Resumption of Direct Oral Anticoagulants Following Polypectomy
The goal of this prospective randomized non-inferiority trial is to compare two different resumption time of Direct Oral Anticoagulants (DOACs) after colonoscopic polypectomy.
- Trial name
- NCT06482333
- Testing
- Time for resumption of DOAC
- Where
- Hong Kong
- Volunteers
- 194 people
- Sponsor
- The University of Hong Kong
Atrial Fibrillation
Comparative Effectiveness of Oral Anticoagulants
This cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the…
- Trial name
- NCT01847547
- Volunteers
- 5,982 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Anticoagulant Adverse Reaction
Precision Medicine Platform for Novel Oral Anticoagulants
The anticoagulants have been developed with new generation for FDA-approved indications including treatment and prevention of venous, pulmonary, and systemic thromboembolism.
- Trial name
- NCT04056143
- Testing
- Pharmacogenomics
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie